Comparison of Several Benzodiazepine Receptor Ligands in Two Models of Anxiolytic Activity in the Mouse: an Analysis Based on Fractional Receptor Occupancies

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1994 Mar 1

PMID 7838907

Citations 14

Authors

G H Jones

C Schneider

H H SCHNEIDER

J Seidler

B J Cole

D N Stephens

Affiliations

Soon will be listed here.

Abstract

This study compared the effects of the beta-carboline anxiolytic, abecarnil, with other benzodiazepine receptor (BZR) ligands, including the full agonists diazepam and alprazolam, and the partial agonists ZK 95962 and bretazenil (Ro 16-6028), and alpidem, in the mouse four-plate test and plus-maze. The efficacy and potency of each compound was related to the fraction of BZR occupied by the drug. Abecarnil was efficacious in both tests and showed anxiolytic effects comparable with alprazolam and diazepam. In the four-plate test, abecarnil, bretazenil, and ZK 95962 had selective effects on releasing exploratory locomotor activity suppressed by footshock (punished crossings). None of these compounds significantly altered non-punished crossings. In contrast, diazepam and alprazolam increased both unpunished and punished crossings at low to medium doses (receptor occupancies of approximately 20-60%). The number of punished and unpunished crossings fell to control levels or below at higher, more sedative doses (approximately 80% receptor occupancy). Alpidem had very weak anxiolytic-like effects in this test and markedly reduced unpunished crossings at relatively low receptor occupancies (> 15%). In the plus-maze, abecarnil increased the time spent in the open arms and the percentage open arm entries to an extent equal to that observed following diazepam or alprazolam administration. Bretazenil and ZK 95962 had weak effects on the measures of anxiolytic activity in this test. Alpidem also had little anxiolytic-like activity in the plus-maze but markedly reduced the total number of arm entries.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Imepitoin Shows Benzodiazepine-Like Effects in Models of Anxiety.

Engel O, Masic A, Landsberg G, Brooks M, Mills D, Rundfeldt C Front Pharmacol. 2018; 9:1225.

PMID: 30455643 PMC: 6230983. DOI: 10.3389/fphar.2018.01225.

Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Duke A, Meng Z, Platt D, Atack J, Dawson G, Reynolds D J Pharmacol Exp Ther. 2018; 366(1):145-157.

PMID: 29720564 PMC: 5988000. DOI: 10.1124/jpet.118.249250.

Blonanserin - A Novel Antianxiety and Antidepressant Drug? An Experimental Study.

Limaye R, Patil A J Clin Diagn Res. 2016; 10(9):FC17-FC21.

PMID: 27790460 PMC: 5071960. DOI: 10.7860/JCDR/2016/19347.8530.

Evaluation of Anxiolytic, Sedative-hypnotic and Amnesic Effects of Novel 2-phenoxy phenyl-1,3,4-oxadizole Derivatives Using Experimental Models.

Tabatabai S, Rezaee Zavareh E, Reyhanfard H, Alinezhad B, Shafaghi B, Sheikhha M Iran J Pharm Res. 2015; 14(Suppl):51-7.

PMID: 26185505 PMC: 4499426.

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

Ripley T, Sanchez-Roige S, Bullmore E, Mugnaini M, Maltby K, Miller S Psychopharmacology (Berl). 2015; 232(18):3431-41.

PMID: 26141191 PMC: 4537503. DOI: 10.1007/s00213-015-3995-x.

References

Turski L, Stephens D, Jensen L, Petersen E, Meldrum B, Patel S . Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther. 1990; 253(1):344-52. View

Facklam M, Schoch P, HAEFELY W . Relationship between benzodiazepine receptor occupancy and potentiation of gamma-aminobutyric acid-stimulated chloride flux in vitro of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 1992; 261(3):1106-12. View

File S, Wilks L, Mabbutt P . Withdrawal, tolerance and sensitization after a single dose of lorazepam. Pharmacol Biochem Behav. 1988; 31(4):937-40. DOI: 10.1016/0091-3057(88)90408-x. View

Aron C, Simon P, Larousse C, BOISSIER J . Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology. 1971; 10(4):459-69. DOI: 10.1016/0028-3908(71)90074-8. View

Stephens D, Meldrum B, WEIDMANN R, Schneider C, Grutzner M . Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity?. Psychopharmacology (Berl). 1986; 90(2):166-9. DOI: 10.1007/BF00181234. View

Obata T, Yamamura H . The effect of benzodiazepines and beta-carbolines on GABA-stimulated chloride influx by membrane vesicles from the rat cerebral cortex. Biochem Biophys Res Commun. 1986; 141(1):1-6. DOI: 10.1016/s0006-291x(86)80325-4. View

Stephens D, SCHNEIDER H . Tolerance to the benzodiazepine diazepam in an animal model of anxiolytic activity. Psychopharmacology (Berl). 1985; 87(3):322-7. DOI: 10.1007/BF00432715. View

Loscher W, Honack D, Scherkl R, Hashem A, Frey H . Pharmacokinetics, anticonvulsant efficacy and adverse effects of the beta-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs. J Pharmacol Exp Ther. 1990; 255(2):541-8. View

BOISSIER J, Simon P, Aron C . A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol. 1968; 4(2):145-51. DOI: 10.1016/0014-2999(68)90170-2. View

10.

Haefely W, Martin J, Schoch P . Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci. 1990; 11(11):452-6. DOI: 10.1016/0165-6147(90)90126-s. View

11.

Miller L, Greenblatt D, Paul S, Shader R . Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther. 1987; 240(2):516-22. View

12.

Pellow S, Chopin P, File S, Briley M . Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985; 14(3):149-67. DOI: 10.1016/0165-0270(85)90031-7. View

13.

Lister R . The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 1987; 92(2):180-5. DOI: 10.1007/BF00177912. View

14.

Steru L, Chermat R, Millet B, Mico J, Simon P . Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects. Epilepsia. 1986; 27 Suppl 1:S14-7. DOI: 10.1111/j.1528-1157.1986.tb05728.x. View

15.

Stephens D, SCHNEIDER H, KEHR W, Andrews J, Rettig K, Turski L . Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther. 1990; 253(1):334-43. View

16.

Potier M, Prado de Carvalho L, Venault P, Chapouthier G, Rossier J . Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo. Eur J Pharmacol. 1988; 156(1):169-72. DOI: 10.1016/0014-2999(88)90161-6. View

17.

Zivkovic B, Morel E, Joly D, Perrault G, Sanger D, Lloyd K . Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry. 1990; 23 Suppl 3:108-13. DOI: 10.1055/s-2007-1014545. View

18.

Facklam M, Schoch P, Bonetti E, Jenck F, Martin J, Moreau J . Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 1992; 261(3):1113-21. View

19.

Durcan M, Lister R . Time course of ethanol's effects on locomotor activity, exploration and anxiety in mice. Psychopharmacology (Berl). 1988; 96(1):67-72. DOI: 10.1007/BF02431535. View

20.

Steppuhn K, SCHNEIDER H, Turski L, Stephens D . Long-term treatment with abecarnil does not induce diazepam-like dependence in mice. J Pharmacol Exp Ther. 1993; 264(3):1395-400. View